Wandercraft Launches Pivotal Clinical Trial of Its Groundbreaking Personal Exoskeleton
New York, NY (February 4, 2025) Wandercraft, a global pioneer in robotic exoskeletons, has announced the start of a landmark clinical trial for the Personal Exoskeleton – the world’s first self-balancing exoskeleton designed for personal use. This groundbreaking device aims to offer upright motion and walking independence for individuals with severe mobility impairments, providing the benefits of standing, walking, bending, reaching, and restoring the feeling of natural walking motion to everyday life.
The pivotal clinical trial is being conducted at the James J. Peters VA Medical Center in the Bronx, NY, and will start soon at the Kessler Institute for Rehabilitation in West Orange, NJ. The study will assess the safety and effectiveness of the Personal Exoskeleton for individuals with spinal cord injuries (SCI).
“The launch of this trial is a major milestone in our journey to redefine what mobility technology can achieve,” said Matthieu Masselin, CEO of Wandercraft. “We’ve seen the profound impact of our exoskeletons in rehabilitation centers, and now we are thrilled to explore how the Personal Exoskeleton could represent a significant leap forward in mobility and walking independence for people with severe walking impairment, starting with SCI, enabling them to walk hands-free without relying on crutches or walkers."
The Personal Exoskeleton is engineered to adapt to users' movements in real time, ensuring smooth walking across diverse surfaces (e.g., carpet, concrete, tile). The device is designed not only for mobility but also for reclaiming everyday joys—whether it’s a walk down the aisle, standing eye-to-eye with loved ones, or simply embracing the world with newfound confidence.
The clinical trial is open to adults 18 and older with complete or incomplete motor SCI (at or above the T6 vertebra) who have (or can get) a physically able companion willing to assist during sessions. For those seeking a companion, Wandercraft is establishing a volunteer network to provide assistance to trial participants. Patients and companions must speak English or communicate effectively with a translator.
Those who meet these criteria, or are interested in volunteering to be a companion, are encouraged to contact: clinicaltrials@wandercraft.health
Additional information about the study may be found at: https://clinicaltrials.gov/study/NCT06777576?term=wandercraft&rank=4
About SCI
SCI is a medically complex and life-disrupting condition without a known cure. It presents various symptoms, including loss of sensory or motor control in the lower limbs, trunk, and upper limbs, and impaired autonomic regulation of the body. This impairment can affect bowel, bladder, and sexual functions. Depending on the lesion level, it can also impact breathing, heart rate, blood pressure, and temperature control.
A recent estimate showed that the annual incidence of SCI is approximately 54 cases per one million people in the United States, or about 17,810 new SCI cases each year. The number of people with SCI living in the United States is approximately 294,000 persons.
About Wandercraft
Wandercraft is on a mission to give everyone the opportunity to stand up and walk again. Known for the first-of-its-kind Personal Exoskeleton, Wandercraft is building the next generation of solutions to restore walking ability at home and in rehabilitation, including the Atalante X—a revolutionary tool in use within inpatient and outpatient rehab centers worldwide.
By blending advanced robotics with a deeply human purpose, Wandercraft aims to provide new options for movement and soon transform the way wheelchair users experience walking mobility in their everyday lives. Committed to innovation and accessibility, Wandercraft welcomes collaboration with rehabilitation centers, healthcare professionals, and the broader community of wheelchair users to expand opportunities in modern mobility. For more information, visit www.wandercraft.eu.
Media Contact
Lilly Kofler
Global Head of Marketing & Communications
lilly.kofler@wandercraft.health